Role of the APOE polymorphism in carotid and lower limb revascularization: A prospective study from Southern Italy

PLoS One. 2017 Mar 1;12(3):e0171055. doi: 10.1371/journal.pone.0171055. eCollection 2017.

Abstract

Background: Atherosclerosis is a complex multifactorial disease and the apolipoprotein E (APOE) polymorphism has been associated to vascular complications of atherosclerosis.

Objectives: To investigate the relationship between the APOE genotypes and advanced peripheral vascular disease.

Materials and methods: 258 consecutive patients (201 males and 57 females, mean age 70.83 ± 7.89 years) with severe PVD were enrolled in a 42-months longitudinal study (mean 31.65 ± 21.11 months) for major adverse cardiovascular events. At follow-up genotypes of the APOE polymorphism were investigated in blinded fashion.

Results: As compared with ε3/ε3, in ε4-carriers a significant higher incidence of major adverse cardiovascular events (35.58% vs. 20.79%; p = 0.025) and total peripheral revascularization (22.64% vs. 5.06%; p < 0.001) was observed. Prospective analysis, showed that ε4-carriers have an increased hazard ratio for major adverse cardiovascular events (adjusted HR 1.829, 95% CI 1.017-3.287; p = 0.044) and total peripheral revascularization (adjusted HR = 5.916, 95% CI 2.405-14.554, p <0.001).

Conclusions: The ε4 allele seems to be risk factor for major adverse cardiovascular events, and in particular for total peripheral revascularization in patients with advanced atherosclerotic vascular disease.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study

MeSH terms

  • Aged
  • Alleles*
  • Apolipoproteins E / genetics*
  • Atherosclerosis* / epidemiology
  • Atherosclerosis* / genetics
  • Atherosclerosis* / physiopathology
  • Carotid Arteries*
  • Female
  • Follow-Up Studies
  • Genotype*
  • Humans
  • Incidence
  • Italy / epidemiology
  • Lower Extremity / blood supply*
  • Male
  • Middle Aged
  • Polymorphism, Genetic*
  • Prospective Studies
  • Risk Factors

Substances

  • Apolipoproteins E

Grants and funding

This study was completely supported by “Ministero della Salute”, I.R.C.C.S. Research Program, Ricerca Corrente 2015-2017, Linea n. 2 “Malattie complesse e terapie innovative” and by the “5 x 1000” voluntary contribution.